Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases
Conditions: Melanoma Brain Metastases Interventions: Drug: Bevacizumab; Drug: Ipilimumab; Drug: Nivolumab; Radiation: Hypofractionated stereotactic radiotherapy Sponsors: Melanoma and Skin Cancer Trials Limited Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 11, 2023 Category: Research Source Type: clinical trials
Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma
First-in-class and best-in-class potential in NRAS-mutated melanoma and other RAS/MAPK pathway-altered solid tumors
Naporafenib has been dosed in more than 500 patients to date, establishing its safety, tolerability, and preliminary... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 11, 2023 Category: Pharmaceuticals Source Type: clinical trials
A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma
Conditions: Melanoma Interventions: Drug: Nivolumab +/- ipilimumab; Drug: Nivolumab Sponsors: Bristol-Myers Squibb Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 8, 2023 Category: Research Source Type: clinical trials
Atorvastatin for Preventing Disease Metastasis in Patients With Resected High-Risk Stage IIA Melanoma
Conditions: Clinical Stage IIA Cutaneous Melanoma AJCC v8 Interventions: Drug: Atorvastatin; Drug: Placebo Administration; Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Other: Electronic Health Record Review Sponsors: OHSU Knight Cancer Institute; Oregon Health and Science University; Kuni Foundation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 5, 2023 Category: Research Source Type: clinical trials
Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers
RP1 in combination with cemiplimab demonstrated clinically meaningful improvements in complete response rate and duration of response compared to cemiplimab in the CERPASS clinical trial, but did not meet either of the two primary... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 5, 2023 Category: Pharmaceuticals Source Type: clinical trials
Profiling of Circulating Immune Cells to Uncover Response Signatures to Anti-PD1 Immunotherapy in Melanoma Patients
Conditions: Melanoma Sponsors: University Hospital, Grenoble; Etablissement Fran çais du Sang Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 4, 2023 Category: Research Source Type: clinical trials
A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda ® in Participants With Stage II and III Melanoma
Conditions: Melanoma Interventions: Drug: GME751; Drug: Keytruda - EU; Drug: Keytruda - US Sponsors: Sandoz Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 1, 2023 Category: Research Source Type: clinical trials
Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma
Conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Melanoma; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Unresectable Melanoma Interventions: Procedure: Biospecimen Collection; Drug: Cyclophosphamide; Procedure: Echocardiography; Drug: Fludarabine; Biological: Interleukin-2; Biological: Lifileucel; Procedure: Magnetic Resonance Imaging; Procedure: Multigated Acquisition Scan; Procedure: Tumor Resection Sponsors: University of Kansas Medical Center; National Cancer Institute (NCI); Iovance Biotherapeutics, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 30, 2023 Category: Research Source Type: clinical trials
Immunization With Autologous Dendritic Cells and Tumor Lysates in Melanoma Patients
Conditions: Stage III Malignant Melanoma of Skin AJCC V6; Stage IV Malignant Melanoma of Skin Interventions: Biological: TAPCells vaccine Sponsors: University of Chile Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 30, 2023 Category: Research Source Type: clinical trials
Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma
Conditions: Merkel Cell Carcinoma Interventions: Drug: Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination Sponsors: Melanoma Institute Australia; Bristol-Myers Squibb Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 30, 2023 Category: Research Source Type: clinical trials
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Conditions: Non Small Cell Lung Cancer; Triple Negative Breast Cancer; Hodgkin Lymphoma; Head and Neck Squamous Cell Carcinoma; Malignant Melanoma Interventions: Drug: CTX-8371 Sponsors: Compass Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 29, 2023 Category: Research Source Type: clinical trials
Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation
Conditions: Melanoma; Non-small Cell Lung Cancer Interventions: Other: Evaluation of ctDNA using the F1T after 1 year of immunotherapy Sponsors: Massachusetts General Hospital; Foundation Medicine Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 27, 2023 Category: Research Source Type: clinical trials
Gut and Tumor Microbiome in Patients With Advanced ER-positive and HER2-negative Breast Cancer or Advanced Melanoma Undergoing PD-1 Checkpoint Inhibitor Therapy.
Conditions: Breast Cancer; Melanoma Interventions: Other: Observation Sponsors: BioCorteX Inc; Tempus Labs Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 10, 2023 Category: Research Source Type: clinical trials
A Phase Ⅰb Study on Autologous GC101 TIL Injection for the Treatment of Advanced Melanoma (MIZAR-002)
Conditions: Tumor Infiltrating Lymphocytes; Safety; Melanoma; Efficacy; Adverse Drug Event Interventions: Biological: GC101 TIL Sponsors: Shanghai Juncell Therapeutics Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 7, 2023 Category: Research Source Type: clinical trials
Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
Conditions: Metastatic Uveal Melanoma Interventions: Drug: ZIV-Aflibercept; Drug: Cemiplimab Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Genzyme, a Sanofi Company; Regeneron Pharmaceuticals Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 7, 2023 Category: Research Source Type: clinical trials
